Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
2,915 results
  • Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. [Journal Article]
    J Endocrinol Invest 2019Scappaticcio L, Castellana M, … Trimboli P
  • CONCLUSIONS: Among different categories of ATEs, Graves' hyperthyroidism was the most common thyroid dysfunction, occurring in more than half of cases. Antithyroid drugs should represent the first-line treatment for ALZ-induced GD patients. However, alemtuzumab-induced GD could not be considered as having a more favourable outcome than conventional GD, given the substantial chance to encounter a fluctuating and unpredictable course.
  • Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. [Journal Article]
    Appl Health Econ Health Policy 2019Michels RE, de Fransesco M, … Krol M
  • CONCLUSIONS: The base-case analysis shows that treatment of RRMS with cladribine tablets is cost effective versus alemtuzumab and fingolimod in HDA patients, and cost effective versus natalizumab in RES patients, at a threshold of €50,000. Driven by the lower costs, cladribine tablets were cost effective (dominant) in all base-case analyses. However, given that outcomes are based on indirect comparisons and post hoc subgroup analysis, as well as the uncertainty surrounding the outcomes, the results presented in this paper should be interpreted with caution.
  • Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab. [Journal Article]
    Mult Scler Relat Disord 2019; 35:270-271Aguirre C, Meca-Lallana V, … Vivancos J
  • Alemtuzumab is an anti-CD52 monoclonal antibody approved for the treatment of multiple sclerosis (MS). It produces rapid depletion of T and B lymphocytes, which could predispose to opportunistic infections. We report one patient with MS who develops cytomegalovirus (CMV) primary infection after a third cycle of alemtuzumab, with spontaneous recovery associated with rapid lymphocyte reconstitution.
  • Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. [Journal Article]
    BMC Res Notes 2019; 12(1):497Holmøy T, Fevang B, … Bø L
  • Sporadic fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. To provide a systematic overview, we searched the centralized European Medicines Agency database of suspected adverse reactions related to medicinal products (EudraVigilance) for fatal adverse events associated with treatment with alemtuzumab (Lemtrada®) for multiple sclerosis. Four independe…
  • Prevalence, Risk Factors, Treatment, and Overall Impact of BK Viremia on Kidney Transplantation. [Journal Article]
    Transplant Proc 2019 Jul - Aug; 51(6):1801-1809Malik O, Saleh S, … Waid T
  • BK viremia (BKV) is a recognized and potentially serious problem in renal transplantation. The risk factors and the impact of BKV on renal allograft and patient survival are controversial. This study reports an 8-year, single-center experience on the prevalence, risk factors, and outcomes of BKV in kidney transplant recipients. This is a retrospective analysis of all patients who received a kidne…
New Search Next